ArticleExpert review of proteomics2018
Affinity enrichment for mass spectrometry: improving the yield of low abundance biomarkers.
Article in Expert review of proteomics, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Using proteomics to advance the search for potential biomarkers for preeclampsia: A systematic review and meta-analysis.PloS one · 2019Pooled it
- A Combined Transcriptomics and Proteomics Approach to Identify Immune Signatures in ANCA-Associated Glomerulonephritis.ACR open rheumatology · 2026Article
- Characterization ofMicroorganisms · 2026Article
- PatientProfiler: building patient-specific signaling models from proteogenomic data.Molecular systems biology · 2025Article
- Nylon Affinity Networks Capture and Sequester Two Model Bacteria Spiked in Human Plasma.Pathogens (Basel, Switzerland) · 2025Article
- Mass spectrometry-based discovery and diagnostic validation of T. cruzi antigens in the urine of congenitally infected Chagas Disease patients.PLoS neglected tropical diseases · 2025Article
- A Trapping-Micro-LC-FAIMS/dCV-MS Strategy for Ultrasensitive and Robust Targeted Quantification of Protein Drugs and Biomarkers.Analytical chemistry · 2024Article
- Upconversion Nanoparticle-Based Dot-Blot Immunoassay for Quantitative Biomarker Detection.Analytical chemistry · 2024Article
- Identification of Unambiguous Borrelia Peptides in Human Urine Using Affinity Capture and Mass Spectrometry.Methods in molecular biology (Clifton, N.J.) · 2024Article
- Scorpion Venom as a Source of Antimicrobial Peptides: Overview of Biomolecule Separation, Analysis and Characterization Methods.Antibiotics (Basel, Switzerland) · 2023Review
- Variant biomarker discovery using mass spectrometry-based proteogenomics.Frontiers in aging · 2023Review
- Green Hydrogel Synthesis: Emphasis on Proteomics and Polymer Particle-Protein Interaction.Polymers · 2022Review
- Article
- Microfluidics for Peptidomics, Proteomics, and Cell Analysis.Nanomaterials (Basel, Switzerland) · 2021Review
- Review
- Shotgun proteomics coupled to nanoparticle-based biomarker enrichment reveals a novel panel of extracellular matrix proteins as candidate serum protein biomarkers for early-stage breast cancer detection.Breast cancer research : BCR · 2020Observational
- Potential Inhibitory Effect ofAntibiotics (Basel, Switzerland) · 2020Article
- Evaluation of pathogen specific urinary peptides in tick-borne illnesses.Scientific reports · 2020Article
- Affinity Capture Enrichment versus Affinity Depletion: A Comparison of Strategies for Increasing Coverage of Low-Abundant Human Plasma Proteins.International journal of molecular sciences · 2020Article
- A Critical Review of Bottom-Up Proteomics: The Good, the Bad, and the Future of this Field.Proteomes · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
introductionMass spectrometry (MS) is the premier tool for discovering novel disease-associated protein biomarkers. Unfortunately, when applied to complex body fluid samples, MS has poor sensitivity for the detection of low abundance biomarkers (≪10 ng/mL), derived directly from the diseased tissue cells or pathogens. Areas covered: Herein we discuss the strengths and drawbacks of technologies used to concentrate low abundance analytes in body fluids, with the aim to improve the effective sensitivity for MS discovery. Solvent removal by dry-down or dialysis, and immune-depletion of high abundance serum or plasma proteins, is shown to have disadvantages compared to positive selection of the candidate biomarkers by affinity enrichment. A theoretical analysis of affinity enrichment reveals that the yield for low abundance biomarkers is a direct function of the binding affinity (Association/Dissociation rates) used for biomarker capture. In addition, a high affinity capture pre processing step can effectively dissociate the candidate biomarker from partitioning with high abundance proteins such as albumin. Expert commentary: Properly designed high affinity capture materials can enrich the yield of low abundance (0.1-10 picograms/mL) candidate biomarkers for MS detection. Affinity capture and concentration, as an upfront step in sample preparation for MS, combined with MS advances in software and hardware that improve the resolution of the chromatographic separation can yield a transformative new class of low abundance biomarkers predicting disease risk or disease latency.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.